Beta Bionics launches underwritten public offering
Beta Bionics launched an underwritten public offering of USD 125 million of common stock.
Deal includes a 30-day underwriters’ option to buy up to an additional USD 18.75 million of common shares.
Proceeds earmarked for general corporate purposes, including Mint commercialization, manufacturing expansion, R&D, clinical development, and working capital.
J.P. Morgan, Piper Sandler, Wells Fargo Securities, and Leerink Partners are joint book-running managers.
BBNX•
